Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II
European Journal of Nuclear Medicine and Molecular Imaging · 2026-10 · 53 (12) · 7446-7459
DOI: 10.1007/s00259-026-08074-z ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 15.07.2026. Verfasst von Etienne Aumont und 23 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada. Hauptthemen laut MEDLINE: Positron-Emission Tomography, tau Proteins, Alzheimer Disease, CA1 Region, Hippocampal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Fonds de Recherche du Québec - Santé, Fondation Brain Canada, Institute of Aging.
Abstract (Originalsprache)
PURPOSE: Tau-PET enables in-vivo staging of Alzheimer disease (AD) pathology, including early Braak stage II involvement of the hippocampus. Conventional whole-hippocampus definitions combine heterogeneous subfields and are susceptible to off-target signal that varies across tracers, limiting sensitivity, specificity, and longitudinal interpretability of early tau accumulation. METHODS: Cross-sectional and longitudinal analyses were conducted in the TRIAD (N = 456) and the ADNI (N = 497) observational cohorts with tau-PET with [18F]MK-6240 or [18F]flortaucipir and structural MRI. A CA1-specific Braak stage II region of interest was compared with a whole-hippocampus approach. Outcomes included Braak stage concordance, longitudinal stability, tau-PET progression, and biological plausibility assessed by amyloid-PET burden and extrahippocampal tau signal. RESULTS: Spatial analyses localised early hippocampal tau-PET signal predominantly to the anterior CA1. Whole-hippocampus measures were more frequently influenced by off-target signal consistent with choroid plexus contamination. Participants classified as CA1-based Braak stage II showed higher amyloid-PET burden, more consistent tau accumulation in the Braak stage III region, and more stable longitudinal progression. CA1-based staging yielded fewer discordant classifications and fewer stage regressions at follow-up. CONCLUSION: CA1-specific tau-PET quantification improves biological plausibility and longitudinal consistency of Braak stage II classification by targeting the hippocampal subfield most vulnerable to early tau pathology and mitigating off-target contamination. CA1-based Braak stage II participants showed greater coherence with the biological framework of AD than those staged using the whole hippocampus. Applicable to available PET resolution, this approach may enhance characterisation of early AD and support participant selection in trials targeting preclinical tau accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
- Montreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, H3A 1A1, Canada.
- Department of Neuroradiology, McGill University, Montréal, QC, H3A 1A1, Canada.
- Department of Psychiatry, McGill University, Montréal, QC, H3A 1A1, Canada.
- Lawrence Berkeley National Laboratory, University of California, Berkeley, CA, USA.
Förderung
- Fonds de Recherche du Québec - Santé
- Fondation Brain Canada
- Institute of Aging
- Consortium canadien en neurodégénérescence associée au vieillissement
- Alzheimer's Association
- Weston Brain Institute
- Colin J Adair Charitable Foundation
Zitieren
APA
Aumont, E., Trudel, L., Hall, B. J., Chan, T., Hosseini, S. A., Macedo, A. C., Therriault, J., Arias, J. F., Lebrun, A., Oliva-Lopez, D., Rahmouni, N., Bezgin, G., Stevenson, J., Servaes, S., Fonov, V., Hsiao, C., Hopewell, R., Vitali, P., Klostranec, J., …, & Rosa-Neto, P. (2026). Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II. European Journal of Nuclear Medicine and Molecular Imaging, 53(12), 7446-7459. https://doi.org/10.1007/s00259-026-08074-z
Vancouver
Aumont E, Trudel L, Hall BJ, Chan T, Hosseini SA, Macedo AC, et al. Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(12):7446-7459. doi:10.1007/s00259-026-08074-z
BibTeX
@article{Aumont2026,
author = {Aumont, Etienne and Trudel, Lydia and Hall, Brandon J and Chan, Tevy and Hosseini, Seyyed Ali and Macedo, Arthur C and Therriault, Joseph and Arias, Jaime Fernandez and Lebrun, Aurélie and Oliva-Lopez, Delphine and Rahmouni, Nesrine and Bezgin, Gleb and Stevenson, Jenna and Servaes, Stijn and Fonov, Vladimir and Hsiao, Chris and Hopewell, Robert and Vitali, Paolo and Klostranec, Jesse and Montembeault, Maxime and Iturria-Medina, Yasser and Baker, Suzanne L and Gauthier, Serge and Rosa-Neto, Pedro},
title = {Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {12},
pages = {7446--7459},
doi = {10.1007/s00259-026-08074-z}
}
EUVIMED